ReviewCureus2026
Incretin-Based Therapies in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Emerging Cardiometabolic Disease Modification Beyond Glycemic Control.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) remains a clinically heterogeneous syndrome with limited disease-modifying therapeutic options, particularly among patients with obesity-related cardiometabolic dysfunction. Increasing evidence suggests that obesity-associated HFpEF represents a distinct inflammatory and metabolically active phenotype characterized by visceral adiposity, endothelial dysfunction, congestion physiology, impaired exercise capacity, and adverse cardiac remodeling. Incretin-based therapies, including glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, have recently emerged as promising interventions within this evolving therapeutic landscape. This systematic review evaluated contemporary randomized clinical evidence examining the effects of semaglutide and tirzepatide in obesity-related HFpEF. A comprehensive literature search was conducted across PubMed/MEDLINE, Scopus, and Web of Science for studies published between January 2020 and July 2025. Nine studies met the predefined eligibility criteria, including landmark randomized controlled trials, pooled analyses, and mechanistic imaging and biomarker substudies. Across the included studies, incretin-based therapies consistently improved heart failure-related symptoms, exercise capacity, quality of life, inflammatory biomarkers, and body weight, while also demonstrating favorable effects on structural remodeling, congestion-related physiology, and cardiovascular-kidney interactions. Mechanistic analyses suggested potential benefits involving reductions in left ventricular mass, paracardiac adipose tissue, inflammatory burden, plasma volume expansion, and markers of myocardial and renal injury. Collectively, the current evidence supports the growing role of incretin-based therapies as promising phenotype-oriented interventions in obesity-related HFpEF and raises the possibility that targeted cardiometabolic modulation may influence multiple domains of disease pathophysiology beyond glycemic control alone. However, further long-term studies are needed to clarify their effects on remodeling reversal, arrhythmia burden, and cardiovascular mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.